MONTPELLIER, FRANCE — Sensorion, a clinical-stage biotechnology company focused on therapies for hearing loss disorders, announced a €60 million (~$65M USD) financing through a reserved offering that includes a €20 million (~$22M USD) strategic investment from Sanofi and participation from existing and new healthcare investors.
According to the company, the financing is intended to support progression of Sensorion’s genetic medicine pipeline—particularly SENS-601 (GJB2-GT)—and to continue clinical development activities for SENS-501 (OTOF-GT).
The settlement and delivery of the offering is expected to take place around January 30, 2026, subject to customary conditions.
Financing structure and participating investors
Sensorion said the reserved offering involves the issuance of 214,285,714 new ordinary shares at a subscription price of €0.28 per share, totaling €60 million (~$65M USD). The company stated that Sanofi is investing €20 million (~$22M USD), with the remaining €40 million (~$43M USD) coming from participating investors that include existing shareholders and additional healthcare-focused funds.
The company reported that participating investors include existing shareholders Redmile Group, Artal (advised by Invus), and Sofinnova Partners, as well as U.S. healthcare specialist funds including Cormorant Asset Management, Coastlands Capital, and Sphera Healthcare.
“We welcome Sanofi’s new strategic investment in Sensorion to advance our pipeline of innovative therapies intended to improve the quality of life of patients suffering from hearing disorders. We are very thankful to the top-tier new investors who joined us and express our gratitude to our existing shareholders who have reaffirmed their support in this transaction. With the additional capital, the Company plans to intensify the ongoing efforts to progress the research and development of SENS-601, including the advancement of the program into its clinical development, and to continue the clinical development of SENS-501 program.”
–Nawal Ouzren, Chief Executive Officer of Sensorion
Pipeline focus and upcoming milestones
Sensorion highlighted SENS-601 (GJB2-GT) as a program targeting hearing loss associated with GJB2 mutations, and said the financing is expected to support key catalysts including CTA/IND approval and first cohort enrollment. The company described SENS-601 as its second gene therapy program anticipated to enter the clinic, following SENS-501, which entered clinical development in 2024.
The company also listed upcoming clinical milestones expected in Q1 2026, including:
- SENS-501: cohort two 6-month follow-up data from the Phase 1/2 Audiogene trial
- SENS-401 (Arazasetron): Phase 2a data readout in cisplatin-induced ototoxicity (Notoxis)
- SENS-601 (GJB2-GT): clinical trial application submission
Runway and planned use of proceeds
Sensorion said the net proceeds of the reserved offering are expected to be approximately €56 million (~$61M USD) and are intended to fund research and development activities for its gene therapy programs (SENS-501 and SENS-601) as well as other R&D and corporate overhead expenses.
The company also reported unaudited cash and cash equivalents and short-term deposits of approximately €47.3 million (~$51M USD) as of December 31, 2025, and stated it believes it will have sufficient cash to fund operations until the end of H1 2027. Prior to the reserved offering, Sensorion estimated it could finance activities into Q3 2026.
About Sensorion
Sensorion is a clinical-stage biotechnology company focused on developing therapies to treat, restore, and prevent hearing loss disorders. Its pipeline includes gene therapy programs targeting hereditary deafness as well as small-molecule drug candidates aimed at preventing ototoxic and sudden hearing loss. The company maintains research collaborations with the Institut Pasteur and other institutions.
Source: Sensorion
